Not applicableWithdrawnNCT03266562What this trial is testingEstrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission MammographyWho this might be right forBreast Neoplasm Mayo Clinic
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410559What this trial is testingNeoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerWho this might be right forBreast Cancer Fudan University 189
Testing effectiveness (Phase 2)Looking for participantsNCT06500208What this trial is testingNeoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BCWho this might be right forBreast Cancer Shanghai Jiao Tong University School of Medicine 48
Not applicableStudy completedNCT01385280What this trial is testingPilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerWho this might be right forEstrogen Receptor-positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Cancer+2 more University of Arizona 13
Testing effectiveness (Phase 2)Ended earlyNCT01823835What this trial is testingGDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerWho this might be right forBreast Cancer Genentech, Inc. 152
Testing effectiveness (Phase 2)Ended earlyNCT00892268What this trial is testingAcupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint PainWho this might be right forBreast CancerMenopausal SymptomsPain University of Arizona 68
Testing effectiveness (Phase 2)Looking for participantsNCT07222215What this trial is testingPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Who this might be right forEstrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more Kristina A. Fanucci 297
Early research (Phase 1)UnknownNCT05957939What this trial is testingTargeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical TrialWho this might be right forTNBC - Triple-Negative Breast Cancer Ministry of Health, Saudi Arabia 2
Testing effectiveness (Phase 2)Ended earlyNCT02457910What this trial is testingTaselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerWho this might be right forEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more Vanderbilt-Ingram Cancer Center 30
Not applicableStudy completedNCT02057029What this trial is testingAssessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast CancerWho this might be right forBreast CancerEarly Stage Estrogen Receptor (ER) Positive Breast Cancer Yale University 96
Testing effectiveness (Phase 2)Study completedNCT02069093What this trial is testingOpen-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Novartis Pharmaceuticals 92
Very early researchStudy completedNCT03962647What this trial is testingA 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast CancerWho this might be right forEstrogen Receptor-positive Breast Cancer Vanderbilt-Ingram Cancer Center 31
Not applicableLooking for participantsNCT06401889What this trial is testingEnhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor TherapyWho this might be right forAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8+4 more Mayo Clinic 35
Testing effectiveness (Phase 2)Study completedNCT02630693What this trial is testingTwo Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerWho this might be right forBreast Cancer Canadian Cancer Trials Group 180
Testing effectiveness (Phase 2)Study completedNCT03250676What this trial is testingTrial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerWho this might be right forBreast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more Eisai Inc. 151
Large-scale testing (Phase 3)Active Not RecruitingNCT04650581What this trial is testingFulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorWho this might be right forBreast Cancer Canadian Cancer Trials Group 250
Not applicableStudy completedNCT06525675What this trial is testingStudy to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)Who this might be right forMetastatic Breast CancerAdvanced Breast CancerLuminal Breast Cancer+2 more MedSIR 419
Testing effectiveness (Phase 2)Active Not RecruitingNCT03900637What this trial is testingPersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS RateWho this might be right forBreast Cancer Seoul National University Hospital 122
Testing effectiveness (Phase 2)Study completedNCT00322348What this trial is testingStudy of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal WomenWho this might be right forAdvanced Breast Cancer AstraZeneca 98
Large-scale testing (Phase 3)Study completedNCT02941926What this trial is testingStudy to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCWho this might be right forBreast Cancer Novartis Pharmaceuticals 3,246